1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Scrip 100: Despite advances, we still need an HIV vaccine

 
• By Peter Charlish

The fact that the AIDS pandemic has faded from the news agenda in recent years is a reflection of the perception, in the developed world at least, of HIV disease as a chronic, manageable condition. No longer is the pandemic seen as the threat it once was. So does that mean the AIDS battle is being won?

The fact that the AIDS pandemic has faded from the news agenda in recent years is a reflection of the perception, in the developed world at least, of HIV disease as a chronic, manageable condition. No longer is the pandemic seen as the threat it once was. So does that mean the AIDS battle is being won?

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

More from Therapy Areas